{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:13:45Z","timestamp":1783948425254,"version":"3.55.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":293,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immune checkpoint inhibitors are one of the most remarkable immunomodulatory therapies of current times. Sabatolimab is a high-affinity, humanized anti-TIM-3 monoclonal antibody currently in development for patients with myeloproliferative disorders, including acute myeloid leukemia and myelodysplastic syndromes. By targeting TIM-3, a receptor expressed on various immune effector cells as well as myeloid cells, multiple mechanisms of action that are distinct from canonical immune checkpoint inhibitors are in play \u2013 (i) blockade of TIM-3 and its ligands PtdSer\/galectin-9, (ii) modulation of leukemic cell self-renewal as well as (iii) antibody-dependent phagocytosis of TIM-3\u2013expressing leukemic cells. Novel immunotherapies such as sabatolimab which enhance the antitumor immune response on converging fronts represent the promise of a continuously replenished armoury for the treatment of cancer.<\/jats:p>","DOI":"10.1093\/immadv\/ltac021","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T20:27:25Z","timestamp":1666384045000},"source":"Crossref","is-referenced-by-count":3,"title":["TIM-3: a tumor-associated antigen beyond checkpoint inhibition?"],"prefix":"10.1093","volume":"2","author":[{"given":"Stefan","family":"Barth","sequence":"first","affiliation":[{"name":"Medical Biotechnology and Immunotherapy Research Unit, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town , Cape Town , South Africa"},{"name":"South African Research Chair in Cancer Biotechnology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town , Cape Town , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2790-1963","authenticated-orcid":false,"given":"Krupa","family":"Naran","sequence":"additional","affiliation":[{"name":"Medical Biotechnology and Immunotherapy Research Unit, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town , Cape Town , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"issue":"11","key":"2023101112262383200_CIT0001","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1073\/pnas.41.11.849","article-title":"The natural-selection theory of antibody formation","volume":"41","author":"Jerne","year":"1955","journal-title":"PNAS"},{"key":"2023101112262383200_CIT0002","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"issue":"6","key":"2023101112262383200_CIT0003","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.cell.2012.02.034","article-title":"Antibody-based immunotherapy of cancer: new insights, new targets","volume":"148","author":"Weiner","year":"2012","journal-title":"Cell"},{"key":"2023101112262383200_CIT0004","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.3389\/fmicb.2018.03158","article-title":"Principles of immunotherapy: implication for treatment strategies in cancer and infectious diseases","volume":"9","author":"Naran","year":"2018","journal-title":"Front Microbiol"},{"issue":"1","key":"2023101112262383200_CIT0005","doi-asserted-by":"crossref","first-page":"itaa007","DOI":"10.1093\/immadv\/ltaa007","article-title":"Recent advances in immunotherapies against infectious diseases","volume":"1","author":"Ramamurthy","year":"2020","journal-title":"Immunother Adv"},{"issue":"15","key":"2023101112262383200_CIT0006","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus etesevimabin mild or moderate Covid-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"2023101112262383200_CIT0007","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2023101112262383200_CIT0008","doi-asserted-by":"crossref","first-page":"itab027","DOI":"10.1093\/immadv\/ltab027","article-title":"Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy","volume":"2","author":"Zhou","year":"2022","journal-title":"Immunother Adv"},{"issue":"11","key":"2023101112262383200_CIT0009","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"issue":"5256","key":"2023101112262383200_CIT0010","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"issue":"1","key":"2023101112262383200_CIT0011","doi-asserted-by":"crossref","first-page":"ltac008","DOI":"10.1093\/immadv\/ltac008","article-title":"Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors","volume":"2","author":"de Britto Evangelista","year":"2022","journal-title":"Immunother Adv"},{"key":"2023101112262383200_CIT0012","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2023101112262383200_CIT0013","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"2023101112262383200_CIT0014","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41588-018-0251-4","article-title":"Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome","volume":"50","author":"Gayden","year":"2018","journal-title":"Nat Genet"},{"issue":"5","key":"2023101112262383200_CIT0015","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"2023101112262383200_CIT0016","doi-asserted-by":"crossref","first-page":"itac019","DOI":"10.1093\/immadv\/ltac019","article-title":"Characterization of sabatolimab, a novel immunotherapy with immune-myeloid activity against TIM-3 receptor","volume":"2","author":"Schwartz","year":"2022","journal-title":"Immunother Adv"}],"container-title":["Immunotherapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/advance-article-pdf\/doi\/10.1093\/immadv\/ltac021\/46599188\/ltac021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/2\/1\/ltac021\/52009062\/ltac021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/2\/1\/ltac021\/52009062\/ltac021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T19:08:10Z","timestamp":1697051290000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article\/doi\/10.1093\/immadv\/ltac021\/6768156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/immadv\/ltac021","relation":{},"ISSN":["2732-4303"],"issn-type":[{"value":"2732-4303","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2022,1,1]]},"article-number":"ltac021"}}